In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Switzerland's First PTH Replacement Therapy
Palopegteriparatide for Chronic Hypoparathyroidism
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Atherosclerotic Coronary Plaques in High-Risk Patients
Who benefits from preventive PCI?
- Colorectal Cancer
Insulin Resistance, Obesity, and Progression
- Modern asthma therapies
New data on biologics and triple therapy
- From symptom to diagnosis
Abdominal Pain – Focal Nodular Hyperplasia
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Hepatology and Metabolism